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Abstract 
The effects of active pupillary dilation on automated static threshold perimetry were studied in twenty-
three normal subjects using the Humphrey field analyzer and the 30-2, STATPAC, and FASTPAC programs. 
A decrease in foveal threshold of 1.95 decibels (P = 0.0081), a mean deviation loss of 1.15 decibels (P = 
0.000 1), a decrease in short-term fluctuation (SF) of 0.19 decibels (P = 0.0423), and a decrease in the 
SF2 of 0.56 decibels (P = 0.0374) were found in dilated fields as compared with baseline visual fields in 
the first eye tested. A decrease in foveal threshold of 2.56 decibels (P = 0.0081) and a mean deviation 
loss of 1.43 decibels (P = 0.0001) were found in dilated fields as compared with baseline visual fields in 
the second eye tested. These findings indicate that active pupillary dilation in healthy subjects produces 
statistically significant differences, although these differences may not be clinically significant. To insure 
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ABSTRACT 
The effects of active pupillary dilation on automated static threshold perimetry 
were studied in twenty-three normal subjects using the Humphrey field 
analyzer and the 30-2, STATPAC, and FASTPAC programs. A decrease in foveal 
threshold of 1.95 decibels (P = 0.0081), a mean deviation loss of 1.15 decibels (P = 
0.000 1), a decrease in short-term fluctuation (SF) of 0.19 decibels (P = 0.0423 ), 
and a decrease in the SF2 of 0.56 decibels (P = 0.0374) were found in dilated 
fields as compared with baseline visual fields in the first eye tested. A decrease 
in foveal threshold of 2.56 decibels (P = 0.0081) and a mean deviation loss of 
1.43 decibels (P = 0.0001) were found in dilated fields as compared with baseline 
visual fields in the second eye tested. These findings indicate that active 
pupillary dilation in healthy subjects produces stat istically significant 
differences, although these differences may not be clinically significant. To 
insure repeatable visual fields, consistent pupil diameter should be controlled 
in serial visual field testing. 
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INTRODUCTION 
It is often assumed that automated perimetry is a purely scientific exam. This 
assumption is false because visual field evaluations are psychophysical evaluations 
and are dependent on many variables including the patient's visual, physical, and 
mental status at the time of testing. Thus, most routine visual field tests are 
subjective. Many factors enter into the determination of a visual field and, because 
of this, there is no "one normal" visual field. Fields may vary to some degree in a 
single individual depending on age, number of previous visual fields, size of pupils, 
ambient room illumination, ratio of the background to stimulus illumination, 
patient's attention abilities, clarity of media, refractive error, aphakia, and 
variation in patient response time. Controlling all possible variables is of 
particular importance in evaluating consecutive visual field exams of a patient. 
One of the controllable variables is pupil size. Pupil size regulates the amount of 
light entering the eye and thus effects retinal illuminance. The effects of miotics 
on visual field sensitivity have been well documented. Pupillary miosis causes a 
decrease in both peripheral and central isopters, therefore it has been suggested 
by some that patients under miotic treatment for glaucoma should have visual field 
testing done with their pupils dilated.l Others suggest that the pupil size should just 
be kept constant in consecutive visual field exams to compare baseline visual fields 
with subsequent visual fields.2 Pupil size affects visual field sensitivity because 
acuity falls off rapidly below pupil diameters of approximately 2.0 millimeters (mm) 
and is constant from approximately 2.25 - 5.00 mm.3 In pupils less than 2.0 mm in 
diameter, visual sensitivity decreases because of a reduction in the light that 
reaches the retina and because of the restricted field of view. 3 Pharmacologic 
r_niosis can have a detrimental effect . on visual fields in normal subjects compared 
with baseline findings.3 Therefore, consistent pupil diameter should be controlled 
in serial visual field testing. When the Humphrey field analyzer was used to study 
the effect of 2% piiocarpine, pupillary constriction resulted in decreased threshold 
sensitivities. 4 This decrease in visual sensitivity was attributed to the decrease in 
retinal illumination that occurs with pupillary constriction. 
While the effects of miotics on visual field sensitivity have been well documented, 
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fewer studies have documented the effects of mydriatics on visual field sensitivity. 
Consequences of pupillary mydriasis include decreased accommodation, increased 
retinal illumination, and increased spherical and chromatic aberration . 
Automated perimetry is performed in the mesopic range where pupil size is often 
greater than 2 mm in diameter and under these conditions retinal illumination 
varies with pupil size. In 1987, Nugent et al evaluated glaucoma patients on 
pilocarpine therapy with kinetic perimetry before and after administration of 2.5% 
phehylephrine and found a significant increase in the visual field area after the 
administration of phenylephrine (unpublished data; presented at the 1987 AAO 
m~eting)S. The effects of pupillary dilation on visual fields were studied on normal 
subjects 30 minutes after instillation of 1% tropicamide by Undenmuth et al.S 
Their findings indicate that complete pupillary dilation in healthy subjects not 
receiving ocular medications produced statistically significant decreases in certain 
visual field measurements. 
Currently, in the interest of time management, many eye care practitioners 
perform visual field testing while waiting for the pupil to fully dilate. There is a 
lack of data to support the assumption that the mydriatic process does not adversely 
affect automated perimetry. The purpose of this study is to determine what affect, if 
any, the dynamic process of mydriasis has on the visual field while keeping other 
variables constant. 
METHODS 
Twenty- three healthy third year optometry students, between the ages of 22-36 
years (mean, 26.8 years; standard deviation[SD] 4.2 years) volunteered to participate 
in the study. The study was approved by the Institutional Review Board of Pacific 
University. A written, informed consent was signed by each participant. 
Participants selected for this study were required to be free of ocular disease, with 
visual acuity correctable to 20/20 Snellen. A comprehensive visual exam done 
within the past year was required of all prospective subjects to insure absence of 
ocular pathology and correction to best distance and near Snellen acuity. · A 
previous visual field test within the past six months vvas also required to reduce the 
learning curve effect. Initial evaluations were conducted to evaluate baseline 
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status of the subject's pupillary measurements, intra-ocular pressure, and visual 
fields. Pupillary measurements were done using a PO rule to the nearest 0.5 mm at 
standard background illumination(32 apostilbs). Intraocular pressures were 
measured using the Goldmann tonometer. Baseline automated perimetry ,.vas 
performed on each eye of all subjects 'rvith the Humphrey field analyzer 
(Humphrey Instruments, San Leandro, CA). Half of the subject group (randomly 
chosen) began testing with the right eye first and the other half of the subject 
group began testing with the left eye first. On subsequent testing, standard 
protocol for pupillary dilation consisted of the following: 1) Far and near Snellen 
acuities were taken prior to drop instillation. 2) An assessment of the intraocular 
pressure and the width of anterior chamber angle was made. 3) One drop of 1% 
proparacaine, one drop of 1% tropicamide, and one drop of 2.5% phenylephrine 
were instilled into each of the subject's eyes. Automated perimetry was performed 
on the first eye approximately five minutes after drop instillation. Automated 
perimetry was performed on the second eye approximately fifteen minutes after 
drop instillation or after completion of the testing of the first eye. A trial lens of 
the refractive error correction with the recommended near lens correction was 
used when indicated. Results were compared using the paired Student's t test. P:::::. 
0.05 was considered statistically significant. 
The 30-2 is a program that tests the central 30 degrees of the visual field. Most 
perimetry threshold strategies are determined by the standard psychophysical 
method of measurement using an up and down staircase or bracketing procedure. 
Here a stimulus is presented randomly and threshold is recorded as the dimmest 
target seen. . Threshold is the minimum amount of light energy necessary for 
detection and is the inverse of sensitivity; the higher the threshold the lower the 
sensitivity. The less sensitive areas of the retina require a brighter target to 
stimulate a response. STATPAC is the statistical analysis program for the Humphrey 
field analyzer. STATPAC compares the patient's visual field to an age matched 
normal population. The rASTPAC is a software program designed to shorten the test 
time by bracketing in 3 decibel (dB) steps and crossing the threshold only once. 
The findings compared in this study were foveal threshold, mean deviation (MD), 
short-term fluctuation (SF), short-term fluctuation squared (SF2) pattern standard 
deviation (PSD), pattern standard deviation squared (PSD2) corrected pattern 
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standard deviation (CPSD), corrected pattern standard deviation squared (CPSD2), 
fixation losses, false positive responses and false negative responses. 
Foveal threshold is a measurement of the dimmest stimulus detectable at the fovea. 
MD is the average difference of the threshold values of all points tested between the 
patient's field and an age-matched norm. 
SF is one way of measuring the effect of fatigue on the visual field. SF is calculated 
from repeated threshold determinations at several select locations and is used as a 
measurement of the amount of variability within the field. 
PSD is a measurement of the degree a patient's measured field departs from the age-
matched reference field. A low PSD suggests a smooth hill of vision, while a high 
PSD suggests an irregular hill of vision. 
CPSD is a measurement of the amount of deviation of the patient's hill of vision 
compared to the shape of the hill of vision of the age-matched reference after 
correction of intra-test variability. Similar to the PSD, a high CPSD indicates an 
irregular hill of vision. The STATPAC program utilizes the CPSD to eliminate the 
effects of patient variability and represents irregularities caused by true visual 
field loss only. 
SF, PSD, and CPSD are weighted standard deviations representing the square root of 
the variance. These values are reported in decibels. When statistical analysis is 
applied, it is preferable to analyze the squared values , or variance of SF, PSD, and 
CPSD. 
Patient reliability is enhanced by controlling the variables that may affect the 
visual field results. Reliability parameters are used in most instruments to provide 
a quantitative measure of patient attention during the exam. These include the 
number of false-positive and false-negative responses, and the number of fixation 
losses. A false positive response occurs \Vhen the patient responds that a target has 
been seen, but, none has been presented. A false negative response occurs when 
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the patient does not respond to a very bright stimulus in an area which has already 
been determined to be normal. Fixation is monitored by the Heijl-Krakau method in 
which a target is presented \Vithin the previously mapped blind spot. If the patient 
responds to this presentation, the assumption is that the patient has not maintained 
fixation. 
RESULTS 
The range of baseline pupillary diameter of the first e_ye tested \vas 3.50 mm to 6.00 
mm (mean 5.28 mm, SO 0. 77 mm). The range of baseline pupillary diameter of the 
second eye tested was also 3.50 mm to 6.00 mm (mean 5.26 mm, SO 0.82 mm). 
Approximately fifteen minutes after administration of one drop each of 1% 
proparacaine, 1% tropicamide, and 2.5% phenylephrine, the pupillary diameter of 
the first eye tested ranged from 4.00 mm to 7.00 mm (mean 5.76 mm, SO 0.98 mm). 
Approximately twenty minutes after administration of the mydriatic drops, the 
pupillary diameter of the second eye tested ranged from 4.00 mm to 9.00 mm (mean 
7.00 mm, SO 1.22 mm). (See Table I for the means of measured parameters.) 
The baseline refractive error, using the spherical equivalent, ranged from +0.75 0 
to -6.50 0 (mean -1.99, SO 2.03). 
INSERT 'I'ABLE I NEAR HERE 
In the comparisons using parametric data from the first eye, PSD, PSD2, CPSO, 
CPso2, fixation-losses, false-positive responses, and false-negative responses were 
similar between the baseline and the dilated automated visual fields in the first eye 
tested. Foveal threshold, MD, SF, and SF2 were significantly different between the 
baseline and the dilated automated visual fields in the first eye tested. A significant 
decrease of the foveal threshold with an average Joss of 1.95 decibels (dB) (P = 
0.0081) was found. A difference of 1.15 dB was found in the tvJD (P = 0.0001). A 
comparison of the baseline and the dilated assessment showed a significant 
improvement of the SF with an average decrease of 0.19 dB (P = 0.0423); SF2, 0.56 dB 
(P= 0.0374). (See Table II). 
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INSERT TABLE II NEAR HERE 
In addition, comparisons were made of parametric data from the second eye tested. 
Although assessing comparisons of the second eye may not be statistically correct , 
it is representative of the clinical situation. The second eye is in a more advanced 
state of mydriasis. Of all the parameters compared, only foveal threshold and rvm 
were significantly different between the baseline and the dilated automated visual 
fields for the second eye tested. A significant decrease of the foveal threshold ,,vith 
an average loss of 2.56 dB (P = 0.0001) 'vvas found. The rvro was greater by 1.43 dB (P = 
0.0001). (See Table III). 
INSERT TABLE III NEAR HERE 
In the first eye tested, subject-specific information showed that dilation had a 
detrimental effect on the mean deviation in 83% (n = 19) and showed an 
improvement of the mean deviation in 17% (n = 4) of subjects compared with 
baseline. In the second eye tested, subject-specific information showed that 
dilation had a detrimental effect on the mean deviation in 96% (n = 22) and showed 
an improvement of the mean deviation in 4% (n = 1) of subjects compared with 
baseline. 
DISCUSSION 
Many eye care practitioners perform visual field testing while \Vaiting for the 
pupil to dilate for the dilated fundus exam. The problem facing practitioners is a 
lack of data ,,vhich supports the assumption that the mydriatic process does not 
adversely affect automated perimetry. Consequences of pupillary mydriasis include 
decreased accommodation, increased retinal illumination, and increased spherical 
and chromatic aberrations. The purpose of this study was to compare baseline 
visual field parameters to visual field parameters during the process of dilation. 
Visual field performance is thought to be minimally influenced by mydriasis, other 
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than the decrease in accommodation.6 To reduce the effec ts ~f accommodation a 
manifest refraction done within the past year was required of all subjects in this 
study to insure correction to best distance and near Snellen acuity. A trial lens of 
the refractive error correction with the recommended near lens correction was 
used when indicated. With automated perimetry testing under mesopic conditions, 
increased retinal illumination occurs with mydriasis.7 It ·would be expected that 
threshold sensilivity values would improve with increased retinal illumination. 
The Stiles-Crawford effect states that light entering the center of the pupillary axis 
produces a greater sensation of brightness than light entering off of the pupillary 
axis. 8 In mydriasis, the Stiles-Crawford effect would decrease this expected 
improvement of threshold sensitivity values. Spherical and chromatic aberration 
result in a blurred image and are increased with larger pupil sizes. In addition to 
accommodative factors and the Stiles-Crawford effect, spherical and chromatic 
aberration may contribute to a decline in threshold sensitivities. In a previous 
study by Lindenmuth et aJS, a decline in foveal threshold sensitivity with ft.ill 
mydriasis was found. Likewise, our study found a decline in foveal threshold 
sensitivity during the active mydriatic process, to be statistically significant, but 
not necessarily clinically significant. In our study the foveal threshold decreased 
an average of 1.95 dB with the first eye tested and 2.56 dB with the second eye tested. 
Although these decreases in foveal threshold are statistically significant at a P s 
0.05, such a loss may not be clinically significant and might occur in normal 
subjects. In accepted clinical criteria for automated perimetry a point in the field 
is not considered abnormal unless it differs from the expected by -+ dB.9 However, a 
loss of 2.5 dB in the foveal threshold may or may not be considered clinically 
significant depending on the criterion used by the clinician. 
MD is based on the mean elevation or depression between the patient's threshold 
and age-matched norms. Lindenmuth et al5 found a worsening of the mean defect 
with complete dilation that was statistically significant, ho'>vever they concluded 
that a change less than J dB may or may not be clinically significant. In our study, 
the MD worsened by 1.15 dB in the first eye tested and by 1.-+3 dB in the second eye 
tested. Although these changes in MD are statistically significant at a P ..:::;0.05, they 
may or may not be clinically significant. 
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SF is an index of the consistency of the subject's responses during the test and is 
obtained by thresholding twice at preselected points. When statistical analysis is 
applied, it is preferable to analyze the SF2. In our study, the SF improved by 0.19 dB 
in the first eye tested, and 0.18 dB in the second eye tested. The SF2 improved by 
0.56 dB in the first eye tested, and 0.58 dB in the second eye tested. The 
improvements in the SF and the SF2 in the first eye tested are statistically 
significant at a P ~ 0.05. The improvements in the SF and SF2 in the second eye 
tested are not statistically significant at a P ~ 0.05. Clinically, SF is considered low if 
less than 1.50 dB. Fluctuation of 1.50 dB to 3.00 dB is medium, and greater than 3.00 
is considered high.lO All SF values with baseline and dilated visual field testing 
were within the normal range, therefore, the improveme11ts in the SF and SF2 are 
not clinically significant. Lindenmuth et alS found no significant change in SF 
and SF2 with full mydriasis. 
PSD measures the degree a patient's measured field departs from the age-normed 
reference field. In a previous study, Lindenmuth et alS found no significant 
change in the PSD . and Pso2 ·with complete mydriasis. Our study also found no 
significant change in the PSD and PSD2 during the active mydriatic process. 
CPSD measures the amount of deviation of the patient's hill of vision compared to 
the shape of the hill of vision of the age-normed reference after correcting of 
intra-test variability. No significant change in the CPSD and CPSD2 was found in 
our study. Interestingly, Lindenmuth et alS found a significant worsening in the 
CPSD and the CPSD2 in fully dilated subjects, which they could not explain. 
Patient reliability parameters include the number of false-positive and false-
negative responses and the number of fixation losses. No significant changes were 
found in these patient reliability parameters. These findings are similar to those 
findings reported by Lindenmuth et als in fully dilated subjects. 
The clinician must always keep in mind the subjective nature of visual field exams 
and be alert to any conditions which may affect the reliability of the results. Every 
effort was made in this study to keep these factors constant, with the only variable 
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in testing conditions being the pupil size. 
Suggestions for future studies might include the following: I) The effects of the 
dynamic process of mydriasis on the visual field of glaucomatous patients treated 
with miotics and 2) The effects of the dynamic process of mydriasis on the visual 
field of a geriatric population. 
The purpose of this study was to determine what affect, if any, the dynamic process 
of mydriasis has on the visual field while keeping other variables constant. Some 
changes in visual field parameters were statistically significant. These changes 
were not necessarily clinically significant depending on the criteria chosen by the 
practitioner. 
Currently, in the interest of time management, many clinicians perform visual 
field testing while waiting for their patient's pupils to completely dilate for the 
dilated fundus exam. This study supports their assumption that the mydriatic 
process does not adversely affect the visual field parameters studied in young 
healthy adults. To avoid any potential inconsistencies in consecutive visual field 
testing, however it is ahvays prudent to control test conditions as closely as possible 
especially on repeated field exams. 
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I FOVEAL THRESI-IJLD M) <F FSD CPSO PUPIL DJM£TER FIXATION LOSS FALSE POSITIVE FALSE. NEGATIVE 
--- ·-
BASELINE 1ST EYE ' 37 . 52 · 0.35 1 56 2.04 0.89 5.28 mm 0 .04 0 02 0 .00 
1ST DILATED I 35 . 57 -1.50 1 37 2 .27 1.40 5.76 mm 0 .04 0 .01 0 .00 
BASELINE 2ND EYE \ 37' 78 -0 . 58 1 56 2 .1 2 1.07 5.26 mm 0.03 l 0 .0 1 0 .02 
2ND DILATED i 35 22 ·2. 0 1 1. 38 2.06 1 .14 7.00 mm 0 Q4 0.01 0 .01 I 
TABLE I. MEANS OF MEASURED PARAMETERS 
FOVEAL THRESHOLD MD SF SF SQUARED PSD PSDSQUARED CPSD CPSD SQUARED 
BASELINE 37.52 -0.35 1.56 2 .54 2 .04 4.41 0.89 1 .54 
DILATED 35.57 -1.50 1.37 1 .98 2 .27 5 .63 1 .40 3.15 I 
MEAN DIFFERENCE 1 .95 -1.15 0.19 0.56 -0 .23 -1.22 -0.51 -1.61 
SO BASELINE 2.02 1 .21 0.32 I 1.07 0 .52 2.62 0 .89 2.44 i 
SO DILATED 3 .03 1.46 0 .32 0 .89 0.71 3 .91 1 . 11 4.18 I 
PVALUES O.Q081 0 .0001 0 .0 423 I 0.0374 
-
0.1466 0 . 157 0 .0564 I 0.069 
TABLE II. COMPARISON OF FIELD MEASUREMENTS FOR FIRST EYE TESTED 
FOVEAL THRESHOLD MD I SF SF SQUARED I PSD PSDSQUARED CPSD CPSD SQUARED 
BASELINE 37.78 -0 .58 1 .56 2 .73 2.12 4~64 1.07 1.66 
-
DILATED 35 .22 -2.01 1.38 2.15 2.06 4.40 1.14 1 .87 -
MEAN DIFFERENCE 2 .56 -1.43 0 .18 0.58 0.06 0.24 -0 .07 -0.21 
SDBASEUNE 1 54 0.94 0 54 1.85 0 .3 9 1.78 0.73 1.68 
SO Olli\T.ED 'i 2 .00 l . U 0.52. 1 . 23 0 .3 9 1.76 0.77 1. 51 
PVALU:ES 
·-
I 0 .0001 0 .000 1 0.256 02S!U' __ '- 0 .4058 0 .4641 0 7107 0 .5956 
TABLE Ill. COMPARISON OF FIELD MEASUREMENTS FOR SECOND EYE TESTED 
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FREQ. DIST: NON DILATED FIRST 
X1: NO FV 
Mean: Std. Dev.: Std . . Error: Variance: Coef. Var.: Count: 
f 
137.522 ,2.02 ,.421 ,4.079 15.383 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 1 
133 140 17 1863 1324 71 lo 1[7 
X2: NO FXL 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,.038 ,.071 ,.015 ,.005 1186.948 123 I 
Minimum: Maximum: Range: Sum: Sum Sguared: # Missing: 2 
lo 1.308 1.308 ,.879 ,.146 lo rv 
I X3: NO MD I Mean : Std. Dev.: Std. Error: Variance: Coef. Var. : Count: I 
1-.349 11.212 , .253 11.47 1-347 .688 123 I I Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 3 I 1-5.3 1.64 15.94 1-8.02 135.133 lo 1/ i I 
X4: NO SF 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,1.562 , .324 1.068 ,.1 05 120.777 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 4 
1.99 12.43 11.44 135.92 158.414 Jo 1[7 
j Xs: NO SF SQ 
,I 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
12.54 ,1.074 ,.224 11.155 142.307 123 I 
Minimum : Maximum: .Range: Sum: Sum Squared: # Missing: 5 
1.98 15.905 ,4.925 158.414 1173.756 lo 17 
• 
FREQ. DIST: NON DILATED FIRST 
' 
Xs: NO PSO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
12.039 1.516 1.108 1.267 125.326 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 6 
11.55 13.74 12.19 146.9 1101.502 (o 1[7 
X7: NO PSO SQ 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,4.413 ,2.618 ,.546 16.854 159.324 123 I 
Minimum: Maximum: RanQe: Sum: Sum Squared: # Missing: 7 
12.402 113.988 111.585 1101.502 1598.738 Jo 1[7 
I X a: NO CPSO Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,.887 ,.886 ,.185 ,.785 199.912 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 8 
' lo 13.25 13.25 120.4 135.371 lo I/ I 
I Xg: NO CPSO SQ Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 11.538 12.44 1.509 15.952 1158.647 123 I 
i Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 9 
lo 110.562 110.562 135.371 1185.349 lo 1[7 
X1o: NO PO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
15.283 1. 766 ,.16 ,.587 114.503 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 1 0 
13.5 Is 12.5 1121.5 1654.75 lo 1[7 
r 
. 
FREQ. DIST: NON DILATED FIRST 
l X11: NO FP Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: ~ · 1.018 ,.045 ,.009 ,.002 1254.576 123 I I Minimum: Maximum: Range: Sum: Sum Squared: # MissinQ: 11 lo 1-167 ,.167 J.4o3 ,.051 lo IV 
X12: NO FN 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
lo lo lo lo I· 123 I 
Minimum: Maximum: Ranse: Sum: Sum Sguared: # Missing: 1 2 
lo lo lo lo lo li 1[7 
f:. j'l 
I · 
FREQ. DIST: DILATED FIRST 
X.1: OIL FV 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
135.565 13.028 1.631 19.166 18.513 123 
Maximum: 
31 42 818 
X2: OIL MD 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
1-1.497 11.462 1.305 12.139 1-97.69 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 2 
1-4.85 j.99 j5.84 1-34.43 198.588 lo IV 
X3: OIL SF 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
11.37 1.322 ,.067 1.104 123.486 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 3 
1.67 12.03 11.36 131.51 145.446 lo 1/ 
X4: OIL SF SQ 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
11.976 1.892 1.186 1.796 145.162 123 I 
. 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 4 
1.449 14.121 13.672 145.446 1107.318 I o 1[7 
Xs: OIL PSD 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
12.268 1· 713 1.149 1.508 131.431 123 I 
Minimum: Maximum: Ranqe: Sum: Sum Squared: # Missing: 5 
11.39 14.26 12.87 152.1 6 1129.467 lo 1[7 
' 
FREQ. DIST: DILATED FIRST 
Xs: OIL PSO sa 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,5.629 13.911 1.815 115.295 169.477 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 6 
11.932 118.148 116.216 1129.467 11 a65.267 Ia 1[7 
X7: OIL CPSO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
11.4a2 11.114 1.232 11.241 179.485 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 7 
Ia 14.a5 14.05 132.24 172.503 I o 1[7 
Xa: OIL CPSO sa 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
13.152 14.175 1.871 117.429 1132.439 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 8 
L Ia 
116.4a2 116.4a2 172.5a3 1611.997 Ia 1/ 
I· 
r 
Xg: OIL PD 
Mean:. Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
15.761 1.975 1.203 1.952 116.933 123 
Minimum: 
4 7 132.5 
f 
X1o: OIL FXL 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
l.a38 1.068 1.014 l.oos 1180.265 123 i 
I Minimum: Maximum: J 
r 0 .286 .867 
FREQ. DIST: DILATED FIRST 
X11: OIL FP 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,.009 ,.042 1.009 ,.002 1479.583 123 I 
Minimum: Maximum: Ranqe: Sum: Sum Squared: # Missinq: 1 1 
lo ,.2 ,.2 ,.2 ,.04 lo 1[7 
X12: OIL FN 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
lo lo lo lo I· 123 
Minimum: 
0 0 0 
FREQ. DIST: NONDILA TED SECOND 
X1: ND FV 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
137.783 11.536 1.32 12.36 ,4.a66 123 I 
Minimum: Maximum: RanQe: Sum: Sum Squared: # Missing: 1 
134 14a Is 1869 132885 Ia 1[7 
X2: NO MD 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
1-.583 1.939 1.196 1.882 1-160.936 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 2 
1-3.64 ,.67 14.31 1-13.42 127.229 Ia 1[7 
f. 
X3: ND SF 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
11.563 ,.543 ,.113 ,.295 134.759 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 3 
1.6 12.7 12.1 135.95 162.685 Ia ll7 
X4: ND SF SQ 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
12.725 11.852 1.386 13.429 167.939 123 I 
Minimum: Maximum: Ranqe: Sum: Sum Squared: # Missinq: 4 
,.36 17.29 16.93 162.685 1246.273 Ia 1[7 
Xs: ND PSD 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
12.119 ,.388 l.a81 ,. 151 118.314 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing : 5 I 11.64 13 .11 11.4 7 148.74 11 a6.6 I a 1[7 
FREQ. DIST: NONDILA TED SECOND 
i 
Xs: NO PSO SQ 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,4.635 11.783 ,.372 ,3.18 138 .478 123 I 
Minimum: Maximum: Ranqe: Sum: Sum Squared: # Missing: 6 
12.69 19.672 16.983 11 a6.6 1564.a35 Ia 1![7 
X7: NO CPSO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,1.a72 1.73 ,.152 ,.533 168.a73 123 I 
Minimum: Maximum: Ranqe: Sum: Sum Squared: # Missing: 7 
J Ia 12.62 12.62 124.66 138.159 Ia 1/ 
Xa: NO CPSO SQ 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,1.659 11.678 ,.35 ,2.817 11a1.16 123 I 
Minimum: Maximum: Ranqe: Sum: Sum Squared: # Missinq: 8 
Ia 16.864 16.864 138.159 1125.28 Ja 1[7 
Xg: NO PO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var. : Count: 
,5.261 ,.824 , .1 72 ,.679 115.661 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing : 9 
r 
13.5 Is 12.5 11 21 1651.5 Ia I/ 
' 
X1 o: NO FXL 
Mean: Std. Dev. : Std. Error: Variance: Coef. Var.: Count: 
,.031 l.a93 l.a19 l.ao9 13a4.207 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 1 0 
Ia 1.429 1.429 1.7a6 1.214 Ia 17 
FREQ. DIST: NONDILA TED SECOND 
I 
X11: NO FP 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,.012 , .04 j.oos ,.002 1342.554 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 1 1 
lo t.167 1167 1.267 1.038 lo 1/ 
X12: NO FN 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var. : Count: 
,.023 ,.05 ,.01 ,.003 1223.331 123 I 
Minimum: Maximum: RanQe: Sum: Sum Squared: # MissinQ: 12 
jo 1.143 ,.143 ,.518 ,.067 lo 1[7 
• s ,, 
FREQ. DIST: DILATED SECOND 
X1: OIL FV 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
135.217 ,1.999 1.417 13.996 15.676 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missin_g: 
131 137 Js 1810 128614 Jo 1/ 
X2: OIL MD 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
1-2.006 11.137 f.237 11 .294 I -56.696 [23 I 
Minimum: Maximum: Range:. Sum: Sum Squared: # Missing: 2 
1-4.57 ) .57 ls.14 1-46.14 1121.02 Jo 1[7 
X3: OIL SF 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
11.375 ,.519 1:108 ,.27 137.782 123 I 
Minimum: Maximum: Ran~e: Sum: Sum Squared: # Missina: 3 
lo ,2.03 12.03 131.62 149.406 I o 1/ 
X4: OIL SF SO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
12.148 11.233 ,.257 . 11.519 157.378 123 I 
Minimum: Maximum: Ran!=le: Sum: Sum Squared: # Missing: 4 
Jo ,4 . 121 ,4.121 149.406 1139.55 lo 1'[7 
! Xs: OIL PSD Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
12.064 ,.386 1.08 ,.149 118.704 123 I I !. Minimum: Maximum: Rar1ge: Sum: Sum Squared: # Missing: 5 
b.58 13.07 11.49 147.47 1101.252 . Jo J/ 
. . 
FREQ. DIST: DILATED SECOND 
Xs: OIL PSO SQ 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
( 4.402 11.757 ,.366 ,3.086 139.905 123 I 
Minimum: Maximum: RanQe: Sum: Sum Squared: # Missing: 6 
12.496 19.425 16.929 1101.252 1513.634 lo 17 
X7: OIL CPSO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
11.142 ,.766 ,.16 1.587 167.075 123 I 
Minimum: Maximum: RanQe: Sum: Sum Squared: # Missing: 7 
lo 12.17 12.17 126.27 142.917 lo 1/ 
X8 : OIL CPSO SQ 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
,1.866 ,1.513 ,.316 ,2.29 181.099 123 
Maximum: 
0 4.709 42.917 
Xg: OIL PO 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
17 11.215 ,.253 11.477 117.363 123 I 
Minimum: Maximum: Range: Sum: Sum Sguared: # Missing: 9 
14 19 (s 1161 11159.5 jo 17 
I X1o: OIL FXL Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
I ,.037 ,.074 ,.015 ,.006 1198.481 123 I Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 1 0 
lo 1.286 1.286 1.861 1.154 I o 1/ 
FREQ. DIST: DILATED SECOND 
X11: OIL FP 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
1.013 ,.033 ,.007 1.001 1267.287 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missing: 1 1 
lo 1. 111 1. 111 1.288 1.028 lo IC7 
X12: OIL FN 
Mean: Std. Dev.: Std. Error: Variance: Coef. Var.: Count: 
1.012 1.039 j.oos 1.001 1332.137 123 I 
Minimum: Maximum: Range: Sum: Sum Squared: # Missinq: 12 
lo 1.143 1.143 1.268 1.036 lo I/ 
FIRST EYE: DILATED VS NONDILATED 
Paired t-Test X1: OIL FV Y1: NO FV 
DF: Mean X- Y: Paired t value: Prob. (2-tail): · 
1-1.957 1-2.909 l.oo81 1 1 
[7 
Paired t-Test X2: OIL MD Y2: NO MD 
Mean X- Y: Paired t value: Prob. (2-tail): DF: 
1-1.148 1-4 .661 1.0001 2 
[7 
Paired t-Test X3: OIL SF Y3: NO SF 
DF: Mean X- Y: Paired t value: Prob. (2-tail): 
1-.192 1-2.156 1.0423 I 3 
7 
Paired t-Test X4: OIL SF SQ Y4: NO SF SQ 
DF: Mean X- Y: Paired t value: Prob. (2-tail): 
1-.564 1-2.215 1.0374 I 4 [[7 
Paired t-Test X5: OIL PSD Y5: NO PSD 
DF: Mean X- Y: Paired t value: Prob. (2-tail): 
1.229 11.505 1.1466 5 
7 
FIRST EYE: DILATED VS NONDILATED 
Paired t-Test Xs: OIL PSO SQ Ys: NO PSO SQ 
Mean X- Y: DF: Paired t value: Prob. (2-tail): 
11.465 1.157 6 [7 
Paired t-Test X7: OIL CPSO Y7: NO CPSO 
DF: Mean X- Y: Paired t value: Prob. (2-tail): 
1.515 1.0564 7 [7 
Paired t-Test Xa: OIL CPSD SQ Ya: NO CPSO SQ 
Mean X- Y: DF: Paired t value: Prob. (2-tail): 
11 .614 1.069 8 [7 
Paired t-Test Xg: OIL PO Yg: NO PO 
Mean X- Y: Paired t value: DF: Prob. (2-tail): 
1.478 12.08 1.0493 
Paired t-Test X1o: OIL FXL Y1o: NO FXL 
DF: Mean X- Y: Paired t value: Prob. (2-tail): 
1-.001 1-.028 1.9776 1 0 
[7 
FIRST EYE: DILATED VS NONDILATED 
Paired t-Test X11: OIL FP Y11: NO FP 
DF: Mean X- Y: Paired t value: Prob. (2-tail): 
1-.009 1-.665 ,.5127 I 1 1 
[7 
Paired t-Test X12: OIL FN Y12: NO FN 
12 
DF: Mean X- Y: Paired t value: 
lo I· I· 
Prob. (2-tafl): 
7 
SECOND EYE: DILATED VS NONDILA TED 
Paired t-Test X1: OIL FV Y1: NO FV 
OF: Mean X- Y: Paired t value: Prob. (2-taill: 
1-2.565 1-5 .232 1.0001 I 1 [7 
OF: Mean X- Y: Paired t value: . Prob. (2-tail): 
1-1 .423 1-6.385 1.0001 2 
7 
Paired t-Test X3: OIL SF Y3 : NO SF 
OF: Mean X- Y: Paired t value: Prob. · (2-tail)_: 
1-.188 1-1.166 1.256 I 3 
7 
Paired t-Test X4: OIL SF Sa Y4: NO SF sa 
OF: Mean X- Y: Paired t value: Prob. (2-tail): 
1-.577 1-1.158 1.2591 4 
Paired t-Test Xs: OIL PSO Y5: NO PSO 
OF: Mean X- Y: Paired t value: Prob. (2-tail): 
1-.055 1-.848 1.4058 5 
[7 
SECOND EYE: DILATED VS NONDILA TED 
Paired t-Test Xs: OIL PSO SQ Ys: NO PSO SQ 
DF: Mean X- Y: Paired t value: Prob. _(2-tail): 
1-.233 1-.745 1.4641 J 6 
v 
Paired · t-Test X7: OIL CPSO Y7: NO CPSO 
Mean X- Y: DF: Paired t value: Prob. (2-tail): j.o7 1.376 1. 7107 7 
v 
Paired t-Test Xa: OIL CPSO SQ Ya: NO CPSO SQ 
DF: Mean X- Y: Paired t value: Prob .. (2-tail): 
,.207 ,.539 1.5956 I 8 
v 
Paired t-Test Xg: OIL PO Vg: NO PO 
DF: Mean X- Y: Paired t value: Pro b . . (2-tail): 
15.455 ,.0001 I 9 
v 
Paired t-Test X1o: OIL FXL Y1o: NO FXL 
DF: Mean X- Y: Paired t value: Prob. (2-tail): 
(.007 1.621 1.5408 I 1 0 
v 
SECOND EYE: DILATED VS NONDILA TED 
Paired t-Test X11: OIL FP Y11: NO FP 
OF: Mean X - Y: Paired t value: Prob. j2-tail): 
1.001 j.os 1.9371 J 1 1 [7 
Paired t-Test X12: OIL FN Y12: NO FN 
OF: Mean X- Y: Paired t value: Prob. (2-tail): 
1-.011 1-.771 1.4492 I 12 
[7 
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OPTOMETRIC SUBMISSION TO IRB 
I. Proiect title 
Is Pupillary Dilation Affecting Your Automated Perimetry 
Results? 
II. Abstract 
Currently, in the interest of time management, many eye care 
practitioners perform visual field testing while waiting for 
their patients' pupils to completely dilate for the eye health 
exam (dilated fundus exam). 
Many previous studies have shown that drugs that cause 
pupillary constriction (miotics) adversely affect the visual field. 
One previous study has shown that drugs that cause pupillary 
dilation (mydriatics) decrease visual field sensitivity when 
pupils are completely dilated. No studies have been done to 
assess visual fields while the patient is in the process of 
mydriasis. The problem facing practitioners, therefore, is a 
lack of data which supports the assumption that the mydriatic 
process does not adversely affect the visual field. 
In the proposed project we will observe what affect, if any, the 
dynamic process of mydriasis has on the visual field 
I I I. Location of project 
The project will involve one location. Initial visual 
examinations and subsequent visual fields testing will be 
conducted at Pacific University Optometry Clinic in Forest 
Grove, Oregon. 
IV. Project oyeryiew 
Disease free, best correctable to 20/20 individuals will be 
selected to participate in this study. A comprehensive visual 
exam done within the past year will be required of all 
prospective subjects to insure absence of ocular pathology and 
correction to best distance and near Snellen acuity. Initial 
evaluations will also be conducted to evaluate the baseline 
status of the subject's pupillary measurements, intra-ocular 
pressure, and baseline visual fields. 
Standard protocol for pupillary dilation will consist of the 
following: 
1 ) Far and near Snellen acuities will be taken prior to drop 
instillation. 
2) Assessment of intraocular pressure and width of anterior 
chamber angle. 
3) Instillation of one drop of 1% proparacaine (local 
anesthetic), one drop of 1% tropicamide (temporarily 
diminishes focusing and inhibits pupillary constriction), 
and one drop of 2.5% phenylephrine (causes pupillary 
dilation) into the subject's eye'-s. 
4) The Humphrey Field Analyzer 30-2 and STATPAC program 
will be utilized to obtain a printout of visual field sensitivity. 
Visual field testing will begin on the first eye five minutes 
after drop instillation. The second eye will be tested after 
testing is completed on the first eye, approximately twenty 
minutes after drop instillation. 
By random selection, half of the subject group will begin with 
testing the right eye first and the other half of the subject 
group will begin testing with the left eye being tested first. 
At the conclusion of the procedure, corneal assessment, lOP 
measurement, and visual acuity assessment will be performed 
on all subjects. 
V. Risks . 
1) No unusual or invasive techniques will be used during the 
visual examinations, only routine optometric tests. Some 
individuals may experience mild headache or fatique after a 
complete exam. 
2) The intraocular pressure will be measured with the 
Goldmann tonometer. Mild to moderate corneal epithelial 
disruption is rarely caused in this procedure as a result 
either of the local anesthetic used or the tonometer probe 
which comes in contact with the corneal surface. 
3) The side effects associated with mydriatic/ cycloplegic 
drugs are pupil enlargement from six to twenty-four hours, 
.light sensitivity, inability to focus at near, and, in very ·rare 
cases, angle closure glaucoma. 
4) Phenylephrine can cause high blood pressure, mainly m 
patients already having elevated blood pressure. 
5) Phenylephrine can exaggerate the effects of systemic 
medications used to treat thyroid disease and high blood 
pressure. 
VI. Procedures to avoid risks 
1) Before the procedure, we will explain the possibility of mild 
headache or fatigue. 
2) To avoid epithelial staining, we will use no more than two 
drops of anesthetic in the eye. Prior to drop instillation, we 
will explain the possibility of mild ocular discomfort and 
offer the patient artificial tears to alleviate any ocular 
discomfort. Any discomfort should be reversed within 
several hours. 
3) We will explain to the subject that their pupils will be larger 
than normal and they will be unable to do nearwork from 6 
to 24 hours after drop instillation. The inability to do near 
work and light sensitivity will be · reversed after 6-24 hours. 
We will also provide sunglasses to the subjects to reduce 
light sensitivity. All precautions will be taken to exclude 
from the study any subject predisposed to angle closure by 
measuring lOP and assessing the width of the anterior 
chamber angle. Angle closure is a very rare side effect but, 
subjects will be monitored for signs and symptoms of the 
situation throughout the procedure. The subjects will be 
informed of the symptoms of angle closure, such as nausea 
and red, painful eye and our home phone numbers will be 
provided to them m case they expenence any of these 
symptoms. 
4) A history will be taken to rule out high blood pressure and 
the patient's blood pressure will be determined before using 
phenylephrine. 
5) Subjects currently taking medicaton for high blood pressure 
or thyroid disorders will be excluded from this study. 
VII. Other pertinent information 
None 
VIII. S i 2 n a t u res 
Gaylene R. Kudrna, Optometry Student 
Mary Stanley, Optometry Student 
Lee Ann Reminton, O.D., Faculty Advisor 
IX. Current and Project Dates 
November. 16. 1992 
Current Date 
November 1992 - May 1993 
Project Dates 
Informed Consent Form 
Institution 





1. Description of project 
Is Pupillary Dilation AffectingYour 
Automated Perimetry Results? 
Gaylene Kudrna 359-4473 
Mary Stanley 3 57-07 44 
Dr. Lee Ann Remington 640-4192 
Pacific University College of Optometry 
Forest grove, Oregon 
Ocular Disease Special Testing 
1993 
This research project is designed to determine what affect, if 
any, the dynamic process of pupillary dilation (mydriasis) has on 
the visual field. Changes in the visual field will be measured by 
having participants complete a baseline eye exam and visual 
fields, which will be compared to the visual field tested during 
mydriasis. Baseline visual fields and visual fields during 
mydriasis will be tested on two separate days with each testing 
time requiring approximately one hour each. Initial evaluations 
will be conducted to determine baseline status of the subjects 
including refraction, slit lamp examination, pupillary 
measurement, intra-ocular pressures, fundus evaluation, and 
baseline visual field. Mydriatic drugs will be instilled into the 
subject's eyes following standard dilation protocol. Visual field 
testing will be performed at specific time intervals after drop 
instillation. 
2. Description of risks 
No unusual or invasive techniques will be used during the 
visual examinations, only routine optometric testing will be 
performed. Some individuals may experience mild headache or 
fatigue after a complete exam. Due to procedures used during 
testing, subjects may temporarily experience pupil enlargement, 
light sensitivity, inability to focus at near, or mild ocular 
discomfort. These symptoms should all resolve within · 6-24 hours. 
Angle closure glaucoma is a rare potential side effect of mydriatic 
drugs in subjects with already elevated intra- ocular pressures 
(lOP) or preexisting anatomical structure that could block aqueous 
outflow of the eye and increase lOP. . All precautions will be taken 
to indentify subjects having this predisposition and those subjects 
will not be chosen to participate in this study. Ocular symptoms 
of angle closure include nausea, and red, painful eye. Subjects are 
advised to call principal investigators in the event that any of 
these symptoms occur. Due to possible drug interaction, 
participants currently taking medication for hypertension or 
thyroid disease will be excluded from participation in this study. 
3. Description of benefits 
This study will serve to increase the subjects basic 
understanding of their visual system. Fees for the visual 
examinations conducted during this study will be waived. 
4. Alternatives adyanta2eous to subjects 
Not applicable 
5. Records of this project will be maintained in a confidential 
manner and no name-identifiable information will be released. 
6. Compensation and medical care 
If you are injured in this experiment it is possible that you will 
not receive compensation or medical care from Pacific University, 
the experimenters, or any organization associated with the 
experiment. All responsible care will be used to prevent injury 
however. 
, 7. Offer to answer any inguiries 
The experimenters will be happy to answer any questions that 
you may have at ariy time during the course of the study. If you 
are not satisfied with the answers you receive, please call Dr. 
James Peterson at 357-0442. During your participation in the 
project you are not a Pacific University clinic patient or client for 
the purposes of the research and all questions should be directed 
to the researchers and/or the faculty advisor who will be solely 
responsible for any treatment (except for an emergency). You will 
not be receiving complete eye, vision or health care as a result of 
participation in the project; therefore you will need to maintain 
your regular program of eye, vision, and health care. 
8. Freedom to · withdraw 
You are free to withdraw your consent and to discontinue 
participation in this project or activity at any time without 
prejudice to you. 
I have read and understand the above. I am 18 years of age or 
over (or this form is signed for me by my parent or guardian). 
Printed name 
Signed --------------------- Date _______ _ 
Address Phone __________ _ 
City---------------------- State/Zip 
Name and address of a person not living with you who will always 
know your address. 
Pacific University 
Institutional Review Board 
Project Disposition Fornl 
Project Title: 
Investigator(s): 
Is Pupillary Dilation Affecting Your Automated Pelimet1y Results? (93-04) 
Gaylene R. Kudma, Mary Stanley 
Faculty Advisor(s): Lee Ann Remington, O.D. 
The IRB met on Janumy 28, 1993 and made the following decision regarding this project 
1. APPROVAL By Mail 
This project is approved based on the materials furnished by the principal investigator (s). Copies of all 
Informed Consent and/or Model Releases must be retained by the principal investigator (s) and upon 
completion of the project delivered to the Director of Research for pennanent storage. Failure to deliver these 
releases at the completion of the project may cause personal legal liability for the principal investigator (s). 
Any occurrence of injury (physical, psychological, etc.) to a subject or any significant change in research 
design must be reported to the Chairperson of the IRB immediately. 
2. APPROVAL WITH MODIFICATIONS REQUIRED D 
The general concept of this project is acceptable as are supporting materials. The IRB requests the following 
modifications be made and reviewed with the Chairperson of the IRB. If modifications are acceptable, (s)he 
will sign and date below. The project us then approved and subject to the conditions stated under item 1 
above. (Human subjects may not be used until the Chairperson signs below.) 
Required Modifications: 
Modifications Accepted: 
Chairperson, JRB Date 
3. DISAPPROVED D 
Because of the reasons listed below, the IRB cannot approve of the use of human subjects in this project. 
The principal investigator (s) may cmTect the problems and resubmit the project to the IRB or may request 
to appear in person at the IRB meeting to explain the project more fully. 
Reasons for Disapproval: 
Chairperson, IRB ---+r;t~'-7'-~...._~---· ________ __.. Date Thursday, January 28, 1993 
